US EditionAstrana Health, Inc. to Participate in Upcoming Investor Conferences
Valneva's senior management will discuss key value drivers and the upcoming VLA15 Phase 3 Lyme disease vaccine data readout, expected from Pfizer in H1 2026.
- Valneva SE's senior management will present and meet investors at upcoming conferences, as announced on March 4, 2026, from Lyon.
- As a specialty vaccine company, Valneva SE said revenues from its growing commercial business help fund continued advancement of its vaccine pipeline.
- Investor meetings include TD Cowen 46th Annual Health Care Conference on March 4 at 11:10am ET in Boston, with additional events in Miami and Amsterdam, with institutional investors and bank representatives.
- Management plans to discuss key value drivers including the VLA15 Phase 3 topline readout Pfizer expects in the first half of 2026, noting the press release contains forward-looking statements subject to risks.
- For investors seeking details, Valneva states that all information and replays are available on www.valneva.com, with contacts including Laetitia Bachelot-Fontaine and D.VP Global Investor Relations.
31 Articles
31 Articles
Montana Standard
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
ALHAMBRA, Calif., March 3, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today…
ivpressonline.com
Inhibrx Announces Participation in Upcoming Scientific Conference
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference:
Hastings Tribune
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Valneva to Participate in Upcoming Investor Conferences
Lyon (France), March 2, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company's key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company's Lyme disease vaccine candidate,…
Coverage Details
Bias Distribution
- 82% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
